Shapiro H, Cowell C, Casper R F
Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.
Fertil Steril. 1993 May;59(5):1055-8. doi: 10.1016/s0015-0282(16)55927-5.
To determine whether vaginal sonographic measurements can be used to monitor the endometrial preparation of recipients in a donor egg program.
Prospective clinical trial.
University hospital-based IVF and donor egg program.
Twelve women without ovarian function.
[1] In a control cycle, patients received 4 or 8 mg of oral E2 and vaginal ultrasound (US) daily until endometrial thickness > or = 6 mm with a triple-line pattern (favorable endometrium) was seen. Progesterone (P) in oil, 100 mg/d, was then added. [2] An endometrial biopsy was performed on day 7 of P therapy. [3] In a treatment cycle, US monitoring of endometrial development during estrogen (E) administration was used; and ET was performed on the 3rd day of P therapy.
In the control cycle, 8 mg/d or 4 mg/d of micronized E2 resulted in favorable endometrium development in all patients in a mean time of 5 and 7 days, respectively. After P treatment, only 1 of 12 endometrial biopsies was in phase. In the treatment cycles, the overall clinical pregnancy rate (PR) was 42%. In those patients with a favorable endometrium in the E replacement phase, before addition of P, the PR was 62.5%. All of the pregnant patients but only 42.8% of the nonpregnant patients had a favorable endometrium on US before the addition of P.
An endometrium that is favorable for implantation can result from the use of a simple fixed dose of E2, with higher doses achieving favorable endometrial development in shorter time. Vaginal sonography of endometrial development before P administration is more accurate than endometrial biopsy in predicting a successful donor egg cycle. Endometrial preparation in donor oocyte programs can be simplified by the use of vaginal US monitoring.
确定阴道超声测量是否可用于监测供卵计划中受者的子宫内膜准备情况。
前瞻性临床试验。
大学附属医院的体外受精和供卵计划。
12名无卵巢功能的女性。
[1] 在对照周期中,患者每日口服4或8mg雌二醇(E2)并进行阴道超声(US)检查,直至子宫内膜厚度≥6mm且呈现三线征(良好的子宫内膜)。然后添加100mg/d的油剂黄体酮(P)。[2] 在P治疗的第7天进行子宫内膜活检。[3] 在治疗周期中,使用超声监测雌激素(E)给药期间的子宫内膜发育情况;并在P治疗的第3天进行胚胎移植(ET)。
在对照周期中,8mg/d或4mg/d的微粒化E2分别使所有患者在平均5天和7天内子宫内膜发育良好。P治疗后,12例子宫内膜活检中只有1例处于相应阶段。在治疗周期中,总体临床妊娠率(PR)为42%。在E替代期子宫内膜良好的患者中,在添加P之前,PR为62.5%。所有妊娠患者但只有42.8%的非妊娠患者在添加P之前超声检查显示子宫内膜良好。
使用简单固定剂量的E2可导致有利于着床的子宫内膜,较高剂量可在更短时间内实现良好的子宫内膜发育。在P给药前对子宫内膜发育进行阴道超声检查比子宫内膜活检在预测供卵周期成功方面更准确。通过使用阴道超声监测可简化供卵计划中的子宫内膜准备过程。